What are the key differences between pregabalin and gabapentin regarding mechanism of action, pharmacokinetics, approved indications, dosing, renal dose adjustments, efficacy, side‑effect profile, and abuse potential?

Key Differences Between Pregabalin and Gabapentin

Pregabalin offers superior pharmacokinetic predictability with linear absorption and faster titration compared to gabapentin, making it easier to dose, though gabapentin may have a better safety profile with fewer adverse events in head-to-head trials.

Mechanism of Action

Both drugs share the same fundamental mechanism: they bind to the α2-δ subunit of voltage-gated calcium channels in the CNS, inhibiting calcium influx and reducing release of excitatory neurotransmitters 1, 2. Neither drug affects GABA receptors directly, binds to plasma proteins, or undergoes hepatic metabolism 2, 3.

Pharmacokinetics: The Critical Distinction

Absorption

• Pregabalin: Linear (first-order) absorption with ≥90% bioavailability regardless of dose. Peak plasma concentration in 1 hour 4, 3
• Gabapentin: Nonlinear (zero-order) saturable absorption. Bioavailability drops from 60% at 900 mg/day to 33% at 3600 mg/day. Peak concentration in 3-4 hours 1, 4

This pharmacokinetic difference is clinically crucial: pregabalin's linear absorption means plasma concentrations increase proportionally with dose, making effects predictable. Gabapentin's saturable absorption makes dosing less predictable and requires more complex titration 1, 4.

Half-Life and Elimination

Both have approximately 6-hour elimination half-lives in normal renal function and are renally excreted unchanged 2, 4. However, in chronic kidney disease, gabapentin half-life extends 10- to 20-fold (52-132 hours) versus only 4-fold for pregabalin 5. This creates a critical safety concern: gabapentin carries substantially elevated dementia risk in CKD patients (HR 7.39 in CKD vs 1.09 without CKD), even at low doses ≤300 mg, suggesting standard renal dose adjustment may be insufficient 5.

Dosing and Titration

Pregabalin 1

• Starting: 50 mg TID or 75 mg BID
• Titration: Increase to 300 mg/day after 3-7 days, then by 150 mg/day every 3-7 days
• Maximum: 600 mg/day (though 300 mg/day often as effective with fewer adverse effects)
• Trial duration: 4 weeks
• Advantage: Can start at therapeutic dose (150 mg/day) without titration 3

Gabapentin 1

• Starting: 100-300 mg at bedtime or TID
• Titration: Increase by 100-300 mg every 1-7 days as tolerated
• Maximum: 3600 mg/day in 3 divided doses
• Trial duration: 3-8 weeks for titration plus 2 weeks at maximum dose
• Disadvantage: Requires slow, careful titration over potentially 2+ months 1

Clinical Efficacy

For neuropathic pain, pregabalin 450 mg/day appears comparable to the predicted maximum effect of gabapentin 4. In the only head-to-head trial for chronic sciatica, gabapentin demonstrated superior pain reduction (VAS reduction: 1.72 vs 0.94, p=0.035) with significantly fewer and less severe adverse events 6. Both drugs showed efficacy in diabetic peripheral neuropathy, postherpetic neuralgia, and partial seizures 1.

Adverse Effects

Common to Both

• Dose-dependent dizziness and sedation 1
• Weight gain 7
• Both require renal dose adjustment 1

Head-to-Head Comparison

In the sciatica trial, pregabalin caused significantly more adverse events (81% vs 19%, p=0.002), especially when taken first 6. This contradicts the theoretical advantage of pregabalin's pharmacokinetics and suggests gabapentin may be better tolerated in real-world use.

Abuse Potential: A Critical Safety Concern

Pregabalin has substantially higher abuse potential than gabapentin 8. In Finnish postmortem toxicology:

• Drug abuse associated with 48.1% of pregabalin findings vs 18.6% of gabapentin findings
• Pregabalin poisoning in 10.1% of cases vs 4.7% for gabapentin
• Among abusers: pregabalin poisoning in 19.1% vs gabapentin 12.5%
• Median blood concentration in abusers: 15 mg/L (pregabalin) vs 12 mg/L (gabapentin)

The mechanism: Pregabalin's rapid absorption and faster onset of action create higher addiction potential 8. Over 90% of gabapentinoid abuse cases involved concurrent opioid use 8.

Renal Impairment: A Major Clinical Pitfall

Both require dose adjustment in renal impairment, but gabapentin poses unique cognitive safety risks in CKD 5:

• In non-dialysis CKD (KDIGO G3b-G4), gabapentin carries HR 4.54 for dementia
• Risk persists even at doses ≤300 mg/day (HR 5.06 in CKD vs 1.27 without CKD)
• Risk attenuates in dialysis patients (HR 1.57), suggesting accumulation in non-dialysis CKD is the driver

Clinical implication: In CKD patients, pregabalin may be the safer choice where cardiovascular risk permits 5.

Drug Interactions

Both have minimal drug interactions. Neither inhibits or induces CYP450 enzymes 2. No clinically significant interactions with:

• Antiepileptics (phenytoin, carbamazepine, valproic acid, lamotrigine)
• Oral contraceptives
• Opioids (oxycodone)
• Benzodiazepines (lorazepam)
• Hypoglycemics 2

Clinical Algorithm for Selection

Choose Gabapentin when:

• Patient has CKD stage 5 on dialysis (pregabalin's advantage diminishes)
• History of substance abuse (lower abuse potential)
• Cost is a major concern
• Patient can tolerate slow titration

Choose Pregabalin when:

• Rapid pain control needed (therapeutic dose achievable in days vs weeks)
• CKD stages 3b-4 (safer cognitive profile than gabapentin)
• Patient requires predictable dosing
• Compliance concerns with TID dosing (pregabalin BID vs gabapentin TID)

Avoid or use extreme caution:

• Pregabalin in patients with substance abuse history
• Gabapentin in non-dialysis CKD patients, especially elderly
• Either drug with concurrent opioids without close monitoring

Approved Indications

Both FDA-approved for 2:

• Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia)
• Partial-onset seizures (adjunctive therapy)

Pregabalin additionally approved for:

• Fibromyalgia 2
• Generalized anxiety disorder (in some countries, not US)

1 1 2 4 3 8 6 5